Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGNA Omega-3 is a dietary supplement developed by Magna Pharmaceuticals, Inc. (Magna Invests) designed to support cardiovascular and cognitive health. Each oral softgel contains 1400 mg of highly concentrated, molecularly distilled fish oil, providing 420 mg of eicosapentaenoic acid (EPA) and 350 mg of docosahexaenoic acid (DHA). These omega-3 fatty acids exert anti-inflammatory and lipid-modulating effects, which contribute to the maintenance of healthy triglyceride levels and overall heart and brain function. The product is sourced from cold-water fish and is molecularly distilled to ensure purity, with testing performed to ensure the absence of pesticides, PCBs, and heavy metals like mercury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MAGNA Omega-3.